Exploring inhibitory potential of Curcumin against various cancer targets by in silico virtual screening

Interdisciplinary Sciences – Computational Life Sciences

Volumn 6, Issue 1, 2014, Pages 13-24

  Mahajanakatti, Arpitha Badarinath ^a   Murthy, Geetha ^b   Sharma, Narasimha ^a,c   Skariyachan, Sinosh ^a  

^a DAYANANDA SAGAR COLLEGE OF ENGINEERING   (India)

^b PES UNIVERSITY   (India)

^c INFOSYS TECHNOLOGIES LTD   (India)

Author keywords

anticarcinogenic; antitumor agents; curcumin; epidermal growth factor; glutathione S transferase Pi gene; litreol; platelet derived growth factor; triterpene; virtual screening

Indexed keywords

3 (PENTADEC 10 ENYL)CATECHOL; 3-(PENTADEC-10-ENYL)CATECHOL; ANTINEOPLASTIC AGENT; ANTIOXIDANT; CATECHOL DERIVATIVE; CURCUMIN; EPIDERMAL GROWTH FACTOR; GLUTATHIONE TRANSFERASE P1; GSTP1 PROTEIN, HUMAN; LIGAND; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR A; PLATELET-DERIVED GROWTH FACTOR A; TRITERPENE;

ALGORITHM; ANIMAL; ARTICLE; CACO 2 CELL LINE; CHEMISTRY; CONFORMATION; DOG; DRUG SCREENING; HUMAN; MDCK CELL LINE; METABOLISM; METHODOLOGY; MOLECULAR DOCKING; NEOPLASM; ORAL DRUG ADMINISTRATION; PROTEIN BINDING;

ADMINISTRATION, ORAL; ALGORITHMS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CACO-2 CELLS; CATECHOLS; CURCUMIN; DOGS; DRUG SCREENING ASSAYS, ANTITUMOR; EPIDERMAL GROWTH FACTOR; GLUTATHIONE S-TRANSFERASE PI; HUMANS; LIGANDS; MADIN DARBY CANINE KIDNEY CELLS; MOLECULAR CONFORMATION; MOLECULAR DOCKING SIMULATION; NEOPLASMS; PLATELET-DERIVED GROWTH FACTOR; PROTEIN BINDING; TRITERPENES;

EID: 84903366939     PISSN: 19132751     EISSN: 18671462     Source Type: Journal    
DOI: 10.1007/s12539-014-0170-8     Document Type: Article

References (55)

1. Aggarwal, B., Sundaram, C., Malani. N., Ichikawa. H. 2007. Curcumin: The Indian solid gold. Adv Exp Med Biol 595, 1–75.
2. Aggarwal, S., Takada, Y., Singh, S., Myers, J.N., Aggarwal B. 2004. Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kB signaling. Int J Cancer 111, 679–692.
3. Aleksandrov, A., Simonson, T. 2010. Molecular dynamics simulations show that conformational selection governs the binding preferences of imatinib for several tyrosine kinases. J Biol Chem 285, 13807–13815.
4. Ammon, H.P., Wahl, M.A. 1991. Pharmacology of Curcuma longa. Planta Med 57, 1–7.
5. Anand, P., Thomas, S.G., Kunnumakkara, A.B., Sundaram, C., Harikumar, K.B., Sung, B., Tharakan, S.T., Misra, K., Priyadarsini, I.K., Rajasekharan, K.N., Aggarwal, B.B. 2008. Biological activities of curcumin and its analogues (Congeners) made by man and mother nature. Biochem Pharmacol 76, 1590–1611.
6. Balius, T.E., Rizzo, R.C. 2009. Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry 48, 8435–8448.
7. Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., Weissig, H., Shindyalov, I.N., Bourne, P.E. 2000. The Protein Data Bank. Nucl Acid Res 28, 235–242.
8. Bustanji, Y., Taha, M.O., Almasri, I.M., Al-Ghussein, M.A., Mohammad, M.K., Alkhatib, H.S. 2009. Inhibition of glycogen synthase kinase by curcumin: Investigation by simulated molecular docking and subsequent in vitro/in vivo evaluation. J Enzyme Inhib Med Chem 24, 771–778.
9. Byron, S.A., Pollock, P.M. 2009. FGFR2 as a molecular target in endometrial cancer. Future Oncol 5, 27–32.
10. Chattopadhyay, I., Biswas, K., Bandyopadhyay, U., Banerjee, R.K. 2004. Turmeric and curcumin biological actions and medicinal applications. Curr Sci 87, 44–50.
11. Chène, P. 2003. Inhibiting the p53-MDM2 interaction: An important target for cancer therapy. Nat Rev Cancer 3, 102–109.
12. Chinnam, M., Goodrich, D.W. 2011. RB1, development, and cancer. Curr Top Dev Biol 94, 129–169.
13. Cicenas, J. 2008. The potential role of Akt phosphorylation in human cancers. Int J Biol Markers 23, 1–9.
14. Curran, J.E., Weinstein, S.R., Griffiths, L.R. 2002. Polymorphic variants of NFKB1 and its inhibitory protein NFKBIA, and their involvement in sporadic breast cancer. Cancer Lett 188, 103–107.
15. Dikshit, R., Gupta, P.C., Ramasundarahettige, C., Gajalakshmi, V., Aleksandrowicz, L., Badwe, R., Kumar, R., Roy, S., Suraweera, W., Bray, F., Mallath, M., Singh, P.K., Sinha, D.N., Shet, A.S., Gelband, H., Jha, P. 2007. Cancer mortality in India: A nationally representative survey. Lancet 379, 1807–1816.
16. Elattar, T.M., Virji, A.S. 2000. The inhibitory effect of curcumin, genistein, quercetin and cisplatin on the growth of oral cancer cells in-vitro. Anticancer Res 20, 1733–1738.
17. Elumalai, M., Muthaiah, R., Alf, M.A. 2012. Identification of curcumin targets in neuroinflammatory pathways: Molecular docking scores with GSK-3beta, p38 MAPK, COX, ICE and TACE enzymes. Acta Pol Pharm 69, 237–245.
18. Greten, F.R, Wagner, M., Weber, C.K., Zechner, U., Adler, G., Schmid, R.M. 2001. TGF alpha transgenic mice. A model of pancreatic cancer development. Pancreatology 1, 363–368.
19. Heidegger, I., Pircher, A., Klocker, H., Massoner, P. 2011. Targeting the insulin-like growth factor network in cancer therapy. Cancer Biol Ther 11, 701–707.
20. Heinlein, C.A., Chang, C. 2004. Androgen receptor in prostate cancer. Endocr Rev 25, 276–308.
21. Hewish, M., Chau, I., Cunningham, D. 2009. Insulinlike growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat Anticancer Drug Discov 4, 54–72.
22. Hockenbery, D.M. 1994. bcl-2 in cancer, development and apoptosis. J Cell Sci Suppl 18, 51–55.
23. Howe, L.R., Subbaramaiah, K., Patel, J., Masferrer, J.L., Deora, A., Hudis, C., Thaler, H.T., Muller, W.J., Du, B., Brown, A.M., Dannenberg, A.J. 2002. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res 62, 5405–5407.
24. Jalili, A., Wagner, C., Pashenkov, M., Pathria, G., Mertz, K.D., Widlund, H.R., Lupien, M., Brunet, J.P., Golub, T.R, Stingl, G., Fisher, D.E., Ramaswamy, S., Wagner, S.N. 2012. Dual suppression of the cyclindependent kinase inhibitors CDKN2C and CDKN1A in human melanoma. J Natl Cancer Inst 104, 1673–1679.
25. Jurenka, J.S. 2009. Anti-inflammatory properties of curcumin, a major constituent of Curcima longa: A review of preclinical and clinical research. Altern Med Rev 14, 141–153.
26. Kanehisa, M., Goto, S. 2000. KEGG: Kyoto encyclopedia of genes and genomes. Nucl Acid Res 28, 27–30.
27. Li, J., Kleeff, J., Giese, N., Büchler, M.W., Korc, M., Friess, H. 2004. Gefitinib (‘Iressa’, ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation. Int J Oncol 25, 203–210.
28. Lin, Y.G., Kunnumakkara, A.B., Nair, A., Merritt, W.M., Han, L.Y., Armaiz-Pena, G.N., Kamat, A.A., Spannuth, W.A., Gershenson, D.M., Lutgendorf, S.K., Aggarwal, B.B., Sood, A.K. 2007. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res 13, 3423–3430.
29. Liu, K.W., Hu, B., Cheng, S.Y. 2011. Platelet-derived growth factor receptor alpha in glioma: A bad seed. Chin J Cancer 30, 590–602.
30. Liu, Z., Liu, L., Li, M., Wang, Z., Feng, L., Zhang, Q., Cheng, S., Lu, S. 2011. Epidermal growth factor receptor mutation in gastric cancer. Pathology 43, 234–238.
31. LoTempio, M.M., Veena, M.S., Steele, H.L., Ramamurthy, B., Ramalingam, T.S., Cohen, A.N., Chakrabarti, R., Srivatsan, E.S., Wang, M.B. 2005. Curcumin suppresses growth of head and neck squamous cell carcinoma. Clin Cancer Res 11, 6994–7002.
32. Machin, P., Catasus, L., Pons, C., Muñoz, J., Matias-Guiu, X., Prat, J. 2002. CTNNB1 mutations and betacatenin expression in endometrial carcinomas. Hum Pathol 33, 206–212.
33. Maekawa, T., Maniwa, Y., Doi, T., Nishio, W., Yoshimura, M., Ohbayashi, C., Hayashi, Y., Okita, Y. 2009. Expression and localization of FOXO1 in nonsmall cell lung cancer. Oncol Rep 22, 57–64.
34. Malavaki, C.J, Roussidis, A.E., Gialeli, C., Kletsas, D., Tsegenidis, T., Theocharis, A.D., Tzanakakis, G.N., Karamanos, N.K. 2013. Imatinib as a key inhibitor of the platelet-derived growth factor receptor mediated expression of cell surface heparan sulfate proteoglycans and functional properties of breast cancer cells. FEBS J 280, 2477–2489.
35. Medina, P.J., Goodin, S. 2008. Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 30, 1426–1447.
36. Mendelsohn, J., Baselga, J. 2006. Epidermal growth factor receptor targeting in cancer. Semin Oncol 33, 369–385.
37. Mohandas, K.M., Desai, D.C. 1990. Epidemiology of digestive tract cancers in India. Indian J Gastroenterol 18, 118–121.
38. Morris, G.M., Goodsell, D.S., Huey, R., Olson, A.J. 1996. Distributed automated docking of flexible ligands to proteins: Parallel applications of AutoDock 2.4. J Comput Aided Mol Des 10, 293–304.
39. Mukhopadhyay, A., Bueso-Ramos, C., Chatterjee, D., Pantazis, P., Aggarwal, B.B. 2001. Curcumin down regulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 20, 7597–609.
40. Re, A., Aiello, A., Nanni, S., Grasselli, A., Benvenuti, V., Pantisano, V., Strigari, L., Colussi, C., Ciccone, S., Mazzetti, A.P., Pierconti, F., Pinto, F., Bassi, P., Gallucci, M., Sentinelli, S., Trimarchi, F., Bacchetti, S., Pontecorvi, A., Lo Bello, M., Farsetti, A. 2011. Silencing of GST-PI, a prostate cancer prognostic gene, by the estrogen receptor-β and endothelial nitric oxide synthase complex. Mol Endocrinol 25, 2003–2016.
41. Russoa, A., Cardile, V., Ioannes, A.D., Garbarino, J. 2009. Effect of litreol on the viability of human cancer cells. Chemico-Biological Interactions 179, 178–184.
42. Sauter, G., Moch, H., Moore, D., Carroll, P., Kerschmann, R., Chew, K., Mihatsch, M.J., Gudat, F., Waldman, F. 1993. Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res 53(10 Suppl), 2199–2203.
43. Seal, A., Aykkal, R., Babu, R.O., Ghosh, M. 2011. Docking study of HIV-1 reverse transcriptase with phytochemicals. Bioinformation 5, 430–439.
44. Siwak, D.R., Shishodia, S., Aggarwal, B.B., Kuzrock, R. 2005. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogenactivated/ extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer 104, 879–890.
45. Skariyachan, S., Mahajanakatti, A.B., Sharma, N., Karanth, S., Rao, S., Rajeswari, N. 2012. Structure based virtual screening of novelinhibitors against multidrug resistant superbugs. Bioinformation 8, 420–425.
46. Stoscheck, C.M., King, L.E. Jr. 1986. Role of epidermal growth factor in carcinogenesis. Cancer Res 46, 1030–1037.
47. Strüh, C.M., Jäger, S., Schempp, C.M., Scheffler, A., Martin, S.F. 2012. A novel triterpene extract from mistletoe induces rapid apoptosis in murine B16.F10 melanoma cells. Phytother Res 26, 1507–1512.
48. Takano, Y., Takenaka, H., Kato, Y., Masuda, M., Mikami, T., Saegusa, M., Okayasu, I. 1999. Cyclin D1 overexpression in invasive breast cancers: Correlation with cyclin-dependent kinase 4 and oestrogen receptor over expression and lack of correlation with mitotic activity. J Cancer Res Clin Oncol 125, 505–512.
49. Wang, D., Veena, M.S., Stevenson, K., Tang, C., Ho, B., Suh, J.D., Duarte, V.M., Faull, K.F., Mehta, K., Srivatsan, E.S., Wang M.B. 2008. Liposomeencapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway. Clin Cancer Res 14, 6228–6236.
50. Wang, Y., Xiao, J., Suzek, T.O., Zhang, J., Wang, J., Zhou, Z. 2012. PubChem’s BioAssay Database. Nucl Acid Res 40, D400–412.
51. Wilken, R., Veena, M.S., Wang, M.B., Srivatsan, E.S. 2011. Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer 10, 12.
52. Xu, G., Chu, Y., Jiang, N., Yang, J., Li, F. 2012. The Three Dimensional Quantitative Structure Activity Relationships (3D-QSAR) and docking studies of curcumin derivatives as androgen receptor antagonists. Int J Mol Sci 13, 6138–6155.
53. Xu, Y.Y., Cao, Y., Ma, H., Li, H.Q., Ao, G.Z. 2013. Design, synthesis and molecular docking of alpha, beta-unsaturated cyclohexanone analogous of curcumin as potent EGFR inhibitors with antiproliferative activity. Bioorg Med Chem 21, 388–394.
54. Yokomizo, A., Kohno, K., Wada, M., Ono, M., Morrow, C.S., Cowan, K.H., Kuwano, M. 1995. Markedly decreased expression of glutathione S-transferase pi gene in human cancer cell lines resistant to buthionine sulfoximine, an inhibitor of cellular glutathione synthesis. J Biol Chem 270, 19451–19457.
55. Yuan, M., Luo, M., Song, Y., Xu, Q., Wang, X., Cao, Y., Bu, X., Ren, Y., Hu, X. 2011. Identification of curcumin derivatives as human glyoxalase I inhibitors: A combination of biological evaluation, molecular docking, 3D-QSAR and molecular dynamics simulation studies. Bioorg Med Chem 19, 1189–1196.